NASDAQ: BWAYBrainsway Ltd Stock
$15.36+0.16 (+1.05%)
Updated Aug 25, 2025
BWAY Price
$15.36
Fair Value Price
-$14.31
Market Cap
$288.97M
52 Week Low
$7.06
52 Week High
$15.61
P/E
51.2x
P/B
4.24x
P/S
5.37x
PEG
2.28x
Dividend Yield
N/A
Revenue
$46.08M
Earnings
$5.34M
Gross Margin
74.5%
Operating Margin
17.17%
Profit Margin
11.6%
Debt to Equity
0.64
Operating Cash Flow
$23M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BWAY Overview
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BWAY's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important BWAY news, forecast changes, insider trades & much more!
BWAY News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BWAY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BWAY ($15.36) is overvalued by 207.36% relative to our estimate of its Fair Value price of -$14.31 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BWAY ($15.36) is not significantly undervalued (207.36%) relative to our estimate of its Fair Value price of -$14.31 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BWAY ($15.36) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BWAY due diligence checks available for Premium users.
Valuation
BWAY fair value
Fair Value of BWAY stock based on Discounted Cash Flow (DCF)
Price
$15.36
Fair Value
-$14.31
Undervalued by
207.36%
BWAY ($15.36) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BWAY ($15.36) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BWAY ($15.36) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BWAY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
51.2x
Industry
32.11x
Market
35.53x
BWAY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BWAY is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
BWAY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.24x
Industry
4.04x
BWAY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BWAY price to earnings growth (PEG)
For valuing profitable companies with growth potential
BWAY is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
BWAY's financial health
Profit margin
Revenue
$12.6M
Net Income
$2.0M
Profit Margin
16%
BWAY's Earnings (EBIT) of $7.91M... subscribe to Premium to read more.
Interest Coverage Financials
BWAY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$111.6M
Liabilities
$43.4M
Debt to equity
0.64
BWAY's short-term assets ($89.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BWAY's short-term assets ($89.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BWAY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BWAY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$12.4M
Investing
-$15.9M
Financing
-$264.0k
BWAY's operating cash flow ($23.17M)... subscribe to Premium to read more.
Debt Coverage Financials
BWAY vs Medical Device Stocks
Brainsway Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.